NCT04443881View on ClinicalTrials.gov

Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

May 8, 2020

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
COVID-19 Pnemonia
Interventions
DRUG

Anakinra 149 MG/ML Prefilled Syringe [Kineret]

Anakinra (100 mg/ 6 hours) i.v infusión during 15 days

Trial Locations (12)

31008

Complejo Hospitalario de Navarra, Pamplona

33394

Hospital Universitario de Cabueñes, Gijón

50009

Hospital Universitario Miguel Servet, Zaragoza

Unknown

Hospital Clinic, Barcelona

Hospital Universitario Vall d´Hebron, Barcelona

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

Hospital Universitario Son Espases, Palma de Mallorca

Hospital Universitario La Paz, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario y Politecnico La Fe, Valencia

Complejo Hospitalario Universitario de Vigo, Vigo

Hospital Clínico Universitario Lozano Blesa, Zaragoza

All Listed Sponsors
lead

Fundacion Miguel Servet

OTHER

NCT04443881 - Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS) | Biotech Hunter | Biotech Hunter